Document is current
Any future updates will be listed below
-
Authors
Kolkhir, Pavel https://orcid.org/0000-0001-5380-8132
Fok, Jie Shen https://orcid.org/0000-0002-3450-0877
Kocatürk, Emek https://orcid.org/0000-0003-2801-0959
Li, Philip H. https://orcid.org/0000-0002-9155-9162
Okas, Tiia-Linda https://orcid.org/0000-0002-9051-240X
Marcelino, Joao https://orcid.org/0000-0001-8462-8847
Metz, Martin https://orcid.org/0000-0002-4070-9976
-
Funding
Funding for this research was provided by:
Charité - Universitätsmedizin Berlin
- License Information
-
More Information
Article History
Accepted: 23 February 2025
First Online: 12 March 2025
Declarations
:
: Open Access funding enabled and organized by Projekt DEAL.
: P.K. was a speaker/consultant and/or advisor for and/or has received research funding from BioCryst, Merus, Novartis, ValenzaBio, and Roche outside of the submitted work. J.F. was a speaker, advisor for, and/ or has received honoraria and/or travel sponsorship from CSL Behring, Takeda, Novartis, Menarini, and Viatris outside of the submitted work. E.K. is/was a speaker and advisor for Novartis, Menarini, LaRoche Posey, Sanofi, Bayer, Abdi İbrahim, and Pfizer outside of the submitted work. P.H.L. was a speaker, advisor for, and has received research funding from Novartis and Sanofi outside of the submitted work. T.L.O. has recieved travel sponsorship from Novartis, Takeda, and Menarini outside of the submitted work. J.M. was a speaker, advisor for, and/ or has received travel sponsorship from Novartis, Sanofi, Takeda, Menarini, AstraZeneca, GlaxoSmithKline, Roxall, Bial, and Medinfar. M.M. is or recently was a speaker and/or advisor for: AbbVie, Advanz, ALK-Abello, Allegria, Almirall, Amgen, Argenx, AstraZeneca, Astria, Attovia, Berlin-Chemie, Celldex, Celltrion, DeepApple, Escient, Galderma, GSK, Incyte, Jasper, Lilly, Novartis, Pfizer, Regeneron, Sanofi, Santa Ana Bio, Septerna, Teva, ThirdHarmonicBio, and Vifor.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: P.K. and M.M. conceived the idea for the review. These authors researched data for the article and worked on the specific parts of the manuscript: P.K. (introduction, conclusion, tables), J.S.F. (anti-KIT), E.K. (BTK inhibitors), P.H.L. (other drugs), T.-L.O. (anti-IL4Rα), and J.M. (other drugs). P.K. combined all parts of the manuscript and wrote the first version of the manuscript under the supervision of and input from M.M. All authors provided feedback on the first draft of the manuscript and its revision and contributed to the discussion of the content. All authors read and approved the final version of the manuscript.
